



DN

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

**Binie V. Lipps**

**Frederick W. Lipps**

Serial No.: 10/716,981

Filed: November 19, 2003

For:

**SYNTHETIC PEPTIDE FOR  
NEUROLOGICAL DISORDERS**

§ ATTY DCKT NO: FWLPAT013US

§

§

§

§

§

§

§

§

§

§

Art Unit: 1647

Examiner:

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT (IDS) TRANSMITTAL  
LETTER/PETITION FOR CONSIDERATION UNDER 37 CFR §1.97**

I. Enclosed is a Form PTO/SB/08B and copies of the cited items.

II. The Examiner is requested to consider each cited item because:

A. ☒ said IDS was filed **BEFORE EXAMINATION:** before the date of the first Office Action on the merits.

Please mail correspondence to:


John R. Casperson

PO Box 2174


Friendswood, Texas 77549


Tel. No. 281-482-2961

Respectfully submitted:

  
John R. Casperson  
Reg. No. 28,198

I hereby certify that this correspondence and all documents referred to herein is being deposited with the United States Postal Service as first class mail in an envelope addressed to the above addressee on

15 May 2006  
 5-15-06  
by John R. Casperson, Reg. No. 28,198 (date)



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/716,981
Filing Date	19 November 2003
First Named Inventor	Lipps, Binie V.
Art Unit	1647
Examiner Name	
Attorney Docket Number	FWLPAT013US

Sheet

1

of

1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HALLER, MF et al "Nerve Growth Factor Delivery Systems" Journal of Controlled Release vol 53, 1-6 (1998)	
		DICOU, ELENI et al "Two Peptides Derived from the nerve Growth Factor Precursor are Biologically Active" J of Cell Biol, Vol 136, No 2, 389-390 (Jan 27, 1997)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.